Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Induction of resistance to chimeric antigen receptor T cell therapy by transduction of a single leukemic B cell
Marco Ruella, Jun Xu, David M. Barrett, et al.
Nature Medicine (2018) Vol. 24, Iss. 10, pp. 1499-1503
Open Access | Times Cited: 534

Showing 1-25 of 534 citing articles:

Engineering strategies to overcome the current roadblocks in CAR T cell therapy
Sarwish Rafiq, Christopher S. Hackett, Renier J. Brentjens
Nature Reviews Clinical Oncology (2019) Vol. 17, Iss. 3, pp. 147-167
Open Access | Times Cited: 1123
Mechanisms of resistance to CAR T cell therapy
Nirali N. Shah, Terry J. Fry
Nature Reviews Clinical Oncology (2019)
Open Access | Times Cited: 836
Recent advances and discoveries in the mechanisms and functions of CAR T cells
Rebecca C. Larson, Marcela V. Maus
Nature reviews. Cancer (2021) Vol. 21, Iss. 3, pp. 145-161
Open Access | Times Cited: 634
An introduction to chimeric antigen receptor (CAR) T‐cell immunotherapy for human cancer
Steven Feins, Weimin Kong, Erik F. Williams, et al.
American Journal of Hematology (2019) Vol. 94, Iss. S1
Open Access | Times Cited: 485
Tumor Immunology and Tumor Evolution: Intertwined Histories
Jérôme Galon, Daniela Bruni
Immunity (2020) Vol. 52, Iss. 1, pp. 55-81
Open Access | Times Cited: 457
Ionizable Lipid Nanoparticle-Mediated mRNA Delivery for Human CAR T Cell Engineering
Margaret M. Billingsley, Nathan Singh, Pranali Ravikumar, et al.
Nano Letters (2020) Vol. 20, Iss. 3, pp. 1578-1589
Open Access | Times Cited: 444
CAR exosomes derived from effector CAR-T cells have potent antitumour effects and low toxicity
Wenyan Fu, Changhai Lei, Shuowu Liu, et al.
Nature Communications (2019) Vol. 10, Iss. 1
Open Access | Times Cited: 374
Side-effect management of chimeric antigen receptor (CAR) T-cell therapy
Maria‐Luisa Schubert, Michael Schmitt, L. Wang, et al.
Annals of Oncology (2020) Vol. 32, Iss. 1, pp. 34-48
Open Access | Times Cited: 360
Engineering and Design of Chimeric Antigen Receptors
Sònia Guedan, Hugo Calderón, Avery D. Posey, et al.
Molecular Therapy — Methods & Clinical Development (2018) Vol. 12, pp. 145-156
Open Access | Times Cited: 348
γδ T cells: pleiotropic immune effectors with therapeutic potential in cancer
Bruno Silva‐Santos, Sofia Mensurado, Seth B. Coffelt
Nature reviews. Cancer (2019) Vol. 19, Iss. 7, pp. 392-404
Open Access | Times Cited: 327
Emerging Cellular Therapies for Cancer
Sònia Guedan, Marco Ruella, Carl H. June
Annual Review of Immunology (2018) Vol. 37, Iss. 1, pp. 145-171
Open Access | Times Cited: 324
Recent advances in CAR-T cell engineering
Ruihao Huang, Xiaoping Li, Yundi He, et al.
Journal of Hematology & Oncology (2020) Vol. 13, Iss. 1
Open Access | Times Cited: 297
Late Events after Treatment with CD19-Targeted Chimeric Antigen Receptor Modified T Cells
Ana Cordeiro, Evandro D. Bezerra, Alexandre V. Hirayama, et al.
Biology of Blood and Marrow Transplantation (2019) Vol. 26, Iss. 1, pp. 26-33
Open Access | Times Cited: 295
Management of adults and children receiving CAR T-cell therapy: 2021 best practice recommendations of the European Society for Blood and Marrow Transplantation (EBMT) and the Joint Accreditation Committee of ISCT and EBMT (JACIE) and the European Haematology Association (EHA)
Patrick Hayden, Claire Roddie, Peter Bader, et al.
Annals of Oncology (2021) Vol. 33, Iss. 3, pp. 259-275
Open Access | Times Cited: 281
Universal CARs, universal T cells, and universal CAR T cells
Juanjuan Zhao, Quande Lin, Yongping Song, et al.
Journal of Hematology & Oncology (2018) Vol. 11, Iss. 1
Open Access | Times Cited: 257
Chimeric antigen receptor natural killer (CAR-NK) cell design and engineering for cancer therapy
Ying Gong, Roel G. J. Klein Wolterink, Jianxiang Wang, et al.
Journal of Hematology & Oncology (2021) Vol. 14, Iss. 1
Open Access | Times Cited: 248
Impaired Death Receptor Signaling in Leukemia Causes Antigen-Independent Resistance by Inducing CAR T-cell Dysfunction
Nathan Singh, Yong Gu Lee, Olga Shestova, et al.
Cancer Discovery (2020) Vol. 10, Iss. 4, pp. 552-567
Open Access | Times Cited: 241
Engineering the next-generation of CAR T-cells with CRISPR-Cas9 gene editing
Alexander Dimitri, Friederike Herbst, Joseph A. Fraietta
Molecular Cancer (2022) Vol. 21, Iss. 1
Open Access | Times Cited: 215
CAR-T Cell Therapy in Hematological Malignancies: Current Opportunities and Challenges
Xiaomin Zhang, Lingling Zhu, Hui Zhang, et al.
Frontiers in Immunology (2022) Vol. 13
Open Access | Times Cited: 209
Genetically engineered T cells for cancer immunotherapy
Dan Li, Xue Li, Weilin Zhou, et al.
Signal Transduction and Targeted Therapy (2019) Vol. 4, Iss. 1
Open Access | Times Cited: 205
Gut microbiome correlates of response and toxicity following anti-CD19 CAR T cell therapy
Melody Smith, Anqi Dai, Guido Ghilardi, et al.
Nature Medicine (2022) Vol. 28, Iss. 4, pp. 713-723
Open Access | Times Cited: 192
Applications of Surface Modification Technologies in Nanomedicine for Deep Tumor Penetration
Zimu Li, Xiaoting Shan, Zhidong Chen, et al.
Advanced Science (2020) Vol. 8, Iss. 1
Open Access | Times Cited: 180
CAR T-cell therapy is effective for CD19-dim B-lymphoblastic leukemia but is impacted by prior blinatumomab therapy
Vinodh Pillai, Kavitha Muralidharan, Wenzhao Meng, et al.
Blood Advances (2019) Vol. 3, Iss. 22, pp. 3539-3549
Open Access | Times Cited: 173
Hypoxia as a driver of resistance to immunotherapy
Joanna Kopecka, Iris C. Salaroglio, Elisabeth Pérez-Ruíz, et al.
Drug Resistance Updates (2021) Vol. 59, pp. 100787-100787
Open Access | Times Cited: 173
Scalable Manufacturing of CAR T Cells for Cancer Immunotherapy
Mohamed Abou‐El‐Enein, Magdi Elsallab, Steven A. Feldman, et al.
Blood Cancer Discovery (2021) Vol. 2, Iss. 5, pp. 408-422
Open Access | Times Cited: 170
Page 1 - Next Page

Scroll to top